TAFI Antibody (16C5): sc-59709

TAFI Antibody (16C5) is a mouse monoclonal IgG1 antibody that detects Thrombin-activatable fibrinolysis inhibitor (TAFI) in human samples through applications such as western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). TAFI is a crucial regulator of fibrinolysis, synthesized in the liver and secreted into the plasma as an inactive zymogen. Upon activation by thrombin, TAFI exerts its function by cleaving C-terminal arginine or lysine residues from various biologically active peptides, including kinins and anaphylatoxins, which plays a significant role in modulating inflammatory responses and coagulation processes. Notably, TAFI′s ability to remove lysine residues from fibrin is vital, as this action inhibits the conversion of plasminogen to plasmin, thereby slowing down the dissolution of fibrin clots. This regulatory mechanism is essential for maintaining hemostatic balance; elevated levels of TAFI are associated with an increased risk of venous thrombosis, while deficiencies can exacerbate bleeding disorders, particularly in hemophilia A and B. Furthermore, decreased TAFI levels are often observed in patients with chronic liver disease, highlighting TAFI′s importance in both coagulation and liver function. Anti-TAFI antibody (16C5) serves as an invaluable tool for researchers studying these critical pathways in hemostasis and thrombosis.

The preferred TAFI antibody is TAFI Antibody (13H4): sc-59708.